Soleno Therapeutics (SLNO) Non Operating Income (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Non Operating Income data on file, last reported at $3.6 million in Q1 2026.

• Non Operating Income for Q1 2026 came in at $3.6 million, up 84.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.1 million (up 12.18% YoY), and the FY2025 annual result was $11.5 million, down 2.92% from the prior year.
• Non Operating Income retreated to $3.6 million in Q1 2026 per SLNO's latest filing, from $3.8 million in the prior quarter.
• Over five years, Non Operating Income peaked at $3.9 million in Q3 2025 and troughed at -$479000.0 in Q3 2023.
• A 5-year average of $1.7 million and a median of $2.0 million in 2025 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2022 and 2023: Non Operating Income surged 2100.0% in 2022, then plunged 574.26% in 2023.
• A 5-year view of Non Operating Income shows it stood at $155000.0 in 2022, then soared by 1586.45% to $2.6 million in 2023, then rose by 19.89% to $3.1 million in 2024, then increased by 20.64% to $3.8 million in 2025, then dropped by 3.86% to $3.6 million in 2026.
• Business Quant data shows SLNO's Non Operating Income at $3.6 million in Q1 2026, $3.8 million in Q4 2025, and $3.9 million in Q3 2025.